In contrast, GLP-1 receptor agonists approved by the FDAincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound, which also activates GIP receptors)are modified to resist DPP-4 degradation
Such products are not subject to quality or safety oversight, carry significant health risks, and are not the same as the investigational compound used in clinical trials
Participants have the right to withdraw from a trial at any time without it affecting their standard NHS care
Nearly three-quarters of US adults are overweight or obese, according to government estimates, but a survey by nonprofit health policy research organisation KFF found only about 8 per cent say they have taken medicine for weight loss
Heres what to know and how to protect yourself